Soluble Vascular Endothelial Growth Factor Receptor 1, and Not Receptor 2, Is an Independent Prognostic Factor in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Cancer

Volumn 100, Issue 9, 2004, Pages 1884-1891

  Hu, Qinglong ^a   Dey, Amanda L ^a   Yang, Ying ^a   Shen, Yu ^a   Jilani, Iman B ^b   Estey, Elihu H ^a   Kantarjian, Hagop M ^a   Giles, Francis J ^a   Albitar, Maher ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

Acute myeloid leukemia (AML); Angiogenesis; Myelodysplastic syndromes (MDS); Prognosis; Vascular endothelial growth factor (VEGF) receptors

Indexed keywords

VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER REGRESSION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MYELODYSPLASTIC SYNDROME; PATIENT ATTITUDE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; SOLUBILITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; ODDS RATIO; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SOLUBILITY; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 1942466613     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20187     Document Type: Article

References (31)

1. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000;60:203-212.
2. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. 1990;5:519-524.
3. Kondo K, Hiratsuka S, Subbalakshmi E, Matsushime H, Shibuya M. Genomic organization of the flt-1 gene encoding for vascular endothelial growth factor (VEGF) receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors. Gene. 1998;208: 297-305.
4. Bussolino F, Albini A, Camussi G, et al. Role of soluble mediators in angiogenesis. Eur J Cancer. 1996;32A:2401-2412.
5. Ferrara N, Bunting S. Vascular endothelial growth factor, a specific regulator of angiogenesis. Curr Opin Nephrol Hypertens. 1996;5:35-44.
6. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9-22.
7. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol. 1998; 140:1255-1263.
8. Pai R, Szabo IL, Kawanaka H, Soreghan BA, Jones MK, Tarnawski AS. Indomethacin inhibits endothelial cell proliferation by suppressing cell cycle proteins and PRB phosphorylation: a key to its antiangiogenic action? Mol Cell Biol Res Commun. 2000;4:111-116.
9. Jiang BH, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA. 2000;97:1749-1753.
10. Suhardja A, Hoffman H. Role of growth factors and their receptors in proliferation of microvascular endothelial cells. Microsc Res Tech. 2003;60:70-75.
11. Schuch G, Machluf M, Bartsch G Jr., et al. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood. 2002;100:4622-4628.
12. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med. 1997;3:1222-1227.
13. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240-2245.
14. Mangi MH, Newland AC. Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol. 2000;111:43-51.
15. Hattori K, Heissig B, Wu Y, et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med. 2002; 8:841-849.
16. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401-409.
17. Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996;77:858-863.
18. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol. 1995;147:33-41.
19. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992;84: 1875-1887.
20. Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst. 1997;89:139-147.
21. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150:815-821.
22. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 2000;95:309-313.
23. Albitar M. Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome. Acta Haematol. 2001;106:170-176.
24. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94:3717-3721.
25. Barleon B, Reusch P, Totzke F, et al. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis. 2001;4:143-154.
26. Belgore FM, Blann AD, Lip GY. sFlt-1, a potential antagonist for exogenous VEGF. Circulation. 2000;102:E108-E109.
27. Belgore FM, Blann AD, Lip GY. Measurement of free and complexed soluble vascular endothelial growth factor receptor, Flt-1, in fluid samples: development and application of two new immunoassays. Clin Sci (Lond). 2001;100:567-575.
28. Pruneri G, Bertolini F, Soligo D, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer. 1999;81:1398-1401.
29. Verstovsek S, Estey E, Manshouri T, et al. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol. 2002;118:151-156.
30. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 2002;109:625-637.
31. Eriksson A, Cao R, Pawliuk R, et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PIGF-1/VEGF heterodimers. Cancer Cell. 2002;1:99-108.